Sernova (FRA:PSH) Receivables Turnover : 0.00 (As of Jan. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sernova Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sernova's Revenue for the three months ended in Jan. 2024 was €0.00 Mil. Sernova's average Accounts Receivable for the three months ended in Jan. 2024 was €0.70 Mil.

Sernova Receivables Turnover Historical Data

The historical data trend for Sernova's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Receivables Turnover Chart

Sernova Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Receivables Turnover

Get a 7-Day Free Trial

Sernova Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sernova's Receivables Turnover

For the Biotechnology subindustry, Sernova's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sernova's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Sernova's Receivables Turnover falls into.

Sernova Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Sernova's Receivables Turnover for the fiscal year that ended in Oct. 2023 is calculated as

	Receivables Turnover (A: Oct. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Oct. 2023 )	/ (	(Accounts Receivable (A: Oct. 2022 )	+	Accounts Receivable (A: Oct. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Sernova's Receivables Turnover for the quarter that ended in Jan. 2024 is calculated as

	Receivables Turnover (Q: Jan. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jan. 2024 )	/ (	(Accounts Receivable (Q: Oct. 2023 )	+	Accounts Receivable (Q: Jan. 2024 ))	/	count )
=	0	/ (	(0	+	0.704)	/	1 )
=	0	/	0.704
=	N/A

Sernova (FRA:PSH) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Sernova Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Sernova's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova (FRA:PSH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (FRA:PSH) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

SEOVF:USA PSH:Germany SVA:Canada

Address

700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.